Let’s start up with the current stock price of Citius Pharmaceuticals Inc. (CTXR), which is $2.35 to be very precise. The Stock rose vividly during the last session to $2.29 after opening rate of $2.14 while the lowest price it went was recorded $2.11 before closing at $2.20.
Recently in News on April 29, 2021, Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar. Citius Pharmaceuticals leads discussion of Mino-Lok’s potential to address biofilm and CLABSI challenges. You can read further details here
Citius Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.90 on 02/22/21, with the lowest value was $1.00 for the same time period, recorded on 01/04/21.
Citius Pharmaceuticals Inc. (CTXR) full year performance was 139.29%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Citius Pharmaceuticals Inc. shares are logging -18.97% during the 52-week period from high price, and 205.19% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.77 and $2.90.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 10277096 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Citius Pharmaceuticals Inc. (CTXR) recorded performance in the market was 115.69%, having the revenues showcasing 80.33% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 284.20M, as it employees total of 10 workers.
Analysts verdict on Citius Pharmaceuticals Inc. (CTXR)
During the last month, 0 analysts gave the Citius Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.57, with a change in the price was noted +1.16. In a similar fashion, Citius Pharmaceuticals Inc. posted a movement of +100.87% for the period of last 100 days, recording 10,065,681 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CTXR is recording 0.02 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Citius Pharmaceuticals Inc. (CTXR): Technical Analysis
Raw Stochastic average of Citius Pharmaceuticals Inc. in the period of last 50 days is set at 58.74%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 79.41%. In the last 20 days, the company’s Stochastic %K was 85.91% and its Stochastic %D was recorded 85.61%.
Let’s take a glance in the erstwhile performances of Citius Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 115.69%. Additionally, trading for the stock in the period of the last six months notably improved by 120.00%, alongside a boost of 139.29% for the period of the last 12 months. The shares increased approximately by 23.60% in the 7-day charts and went up by 23.60% in the period of the last 30 days. Common stock shares were driven by 80.33% during last recorded quarter.